To validate the molecular signature from the regulatory core in breast cancer, we used data from the TRANSBIG network (GEO id: GSE7390; n = 198) generated by Desmedt et al.22 Similar to bladder cancer patients, we observed that the progression-free survival probability of breast cancer patients was low for high expression of E2F1, EGFR, and TGFBR2 in different combinations (Fig. 7d–f). This evidence concerns the gene EGFR and breast carcinoma.